Phase 4
N=50
Septorhinoplasty Post-operative Pain Control With SPG Nerve Block
Deviated Nasal Septum
Bottom Line
View on ClinicalTrials.gov: NCT05667324 ↗Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Post Operative Pain Scores — 3.9; 3.8; 2.7; 2.9 pain score on a scale of 0-10
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Ropivacaine (Drug); Dexamethasone (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Florida
- Primary completion
- Feb 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Post Operative Pain Scores |
3.9; 3.8; 2.7; 2.9; 1.5; 2.1 | — |
| SECONDARY Post Anesthesia Care Unit Duration |
111; 108 | — |
| SECONDARY Text Message Survey Collection |
22; 24; 18; 23; 16; 15 | — |
Summary
Maxillary nerve blocks have been shown to significantly reduce post-operative pain and analgesic intake during the 24-hour period following sinus surgery. This randomized, double-blinded, placebo-controlled study will investigate blocks of the sphenopalatine ganglion using a suprazygomatic approach during septorhinoplasty surgery. It is the investigator's hypothesis that this technique will result in decreased post-operative pain and opioid use, and the morbidity associated with it.
Eligibility Criteria
Inclusion Criteria
- Patient presenting for open or endoscopic septorhinoplasty
- Age 18-80
- Normal oral food and water intake before surgery
- ASA physical classification 1-3
Exclusion Criteria
- Refusal to consent
- Patients without a cellular phone or who are unable to accept text messages
- Allergy to opioid narcotics
- ASA physical classification of 4 or higher
- Patient requires other surgery in addition to septorhinoplasty
- Age > 80 or <18
- Any underlying chronic pain condition or ongoing opioid use over the preceding 3 months
- Presence of any other factor which, at the discretion of any member of the study team, makes the patient a poor candidate for block placement.
- Presence of any other factor which, at the discretion of any member of the study team, makes the patient a poor candidate for research participation.
- Pregnant women
Data sourced from ClinicalTrials.gov (NCT05667324). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.